Evidence map›Paper›PMID 40106118›Full record

ArticleInsights into imaging2025

MRI assessment of body composition for prediction of therapeutic response to biologic agents in patients with Crohn's disease.

Naomi S Sakai, Andrew A Plumb, Norin Ahmed, Kashfia Chowdhury, Yakup Kilic, Maira Hameed, Anisha Patel, Anisha Bhagwanani, Emma Helbren, Rachel Hyland and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Naomi S SakaiCentre for Medical Imaging, University College London, Division of Medicine London, London, UK.
Andrew A PlumbCentre for Medical Imaging, University College London, Division of Medicine London, London, UK.
Norin AhmedComprehensive Clinical Trials Unit, University College London, London, UK.
Kashfia ChowdhuryComprehensive Clinical Trials Unit, University College London, London, UK.
Yakup KilicDepartment of Radiology, University College London Hospitals, London, UK.
Maira HameedCentre for Medical Imaging, University College London, Division of Medicine London, London, UK.
Anisha PatelRadiology Department, Western General Hospital, Edinburgh, UK.
Anisha BhagwananiRadiology Department, Wexham Park Hospital, Frimley Health NHS Foundation Trust, Slough, UK.
Emma HelbrenRadiology Department, Hull University Teaching Hospital NHS Foundation Trust, Hull, UK.
Rachel HylandSt James's University Hospital, Leeds, UK.
Gauraang BhatnagarCentre for Medical Imaging, University College London, Division of Medicine London, London, UK.
Harbir SidhuCentre for Medical Imaging, University College London, Division of Medicine London, London, UK.
Hannah LambieSt James's University Hospital, Leeds, UK.
James M FranklinInstitute of Medical Imaging and Visualisation, Bournemouth University, Bournemouth, UK.
Maryam MohsinSt James's University Hospital, Leeds, UK.
Elen ThomsonSt James's University Hospital, Leeds, UK.
Darren BooneDepartment of Radiology, University College London Hospitals, London, UK.
Damian TolanSt James's University Hospital, Leeds, UK.
Safi RahmanEpsom and St Helier University Hospitals NHS Trust, Epsom, UK.
Nik DingGastroenterology Department, St Vincent's Hospital, Melbourne, VIC, Australia.
Gordon W MoranTranslational Medical Sciences, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK.
Stuart BloomDepartment of Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK.
Ailsa HartSt Mark's the National Bowel Hospital, London, UK.
Alex MenysMotilent, London, UK.
Simon TravisKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Steve HalliganCentre for Medical Imaging, University College London, Division of Medicine London, London, UK.
Stuart A TaylorCentre for Medical Imaging, University College London, Division of Medicine London, London, UK. Stuart.taylor1@nhs.net.ORCID http://orcid.org/0000-0002-6765-8806
Motility trial investigators

Funding

Efficacy and Mechanism Evaluation Programme EME 14/201/16
6 · The paper itself

Abstract

objectivesAltered body fat and muscle mass in Crohn's disease (CD) have been linked to adverse disease course and outcomes. Prediction of treatment response or remission (RoR) of small bowel CD (SBCD) to biologic therapy remains challenging. We aimed to establish the prognostic value of body composition parameters measured using MR enterography (MRE) for RoR at 1 year in patients with SBCD commencing biologic therapy.

methodsParticipants were identified from those recruited to a prospective, multicentre study investigating the predictive ability of motility MRI for 1 year RoR in patients starting biologic therapy for active SBCD (MOTILITY trial). Myopenia, skeletal muscle:fat and visceral:subcutaneous fat were measured from baseline MRE. RoR at 1 year was judged using a composite of clinical and morphological MRE parameters. We compared the likelihood of RoR in patients with and without myopenia or low skeletal muscle:fat using logistic regression models.

resultsNinety-six participants were included (mean age 38.2 years; 40 (42%) female). There were 34 (35%) responders. There was no significant difference in RoR at 1 year between those patients with and without skeletal muscle myopenia (OR: 0.85, 95% CI: 0.27, 2.66, p-value: 0.78), or those with or without low skeletal muscle:fat (OR: 0.71, 95% CI: 0.19, 2.71, p-value: 0.62).

conclusionsBody composition parameters demonstrated no value for predicting therapeutic RoR in patients commencing biologic therapy for SBCD. CRITICAL RELEVANCE STATEMENT: Prediction of response to biologic therapy in small bowel Crohn's disease (SBCD) remains challenging. Body composition parameters cannot predict biologic therapeutic response or remission for SBCD reliably. KEY POINTS: Altered body fat and muscle mass in Crohn's disease have been linked to adverse outcomes. Prediction of response to biologic therapy in small bowel CD (SBCD) would be useful for treatment optimisation. Body composition parameters measured using MRI cannot reliably predict biological therapeutic response or remission for SBCD.

Indexed as

Biological therapyBody compositionCrohn’s diseaseMagnetic resonance imaging

Identifiers

PMID40106118
PMCPMC11923306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.